PRA Health Sciences,Inc. (NASDAQ:PRAH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

PRA Health Sciences,Inc. (NASDAQ:PRAH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December15, 2017, David Dockhorn, Executive Vice President and Corporate Compliance Officer of PRA Health Sciences,Inc. (the “Company” or “PRA”) provided notice of his intent to retire from PRA, effective March30, 2018. Mr.Dockhorn will assist the Company in transitioning his responsibilities to our other executive officers through the date of his departure. Mr.Dockhorn’s retirement is due to his desire to spend more time with his family and personally recharge, and not due to any disagreement with the Company on any matter related to PRA’s operations, practices or policies.


About PRA Health Sciences,Inc. (NASDAQ:PRAH)

PRA Health Sciences, Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The Company’s service offerings include Product Registration Services, which includes Phase IIb through III product registration trials and Phase IV trials, inclusive of post-marketing commitments and registries; Strategic Solutions, which provides Embedded Solutions and functional outsourcing services, and Early Development Services, which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.